Don’t close the book on tocilizumab for the treatment of severe COVID-19 pneumonia–the jury is still out: The Kuwait experience

Abstract

Purpose This cross-sectional observational study aims to report preliminary data from the first experience using tocilizumab for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in three of Kuwait’s largest public hospitals City. Patients and methods This chart review study examined the benefits of tocilizumab treatment among 127 patients diagnosed with severe coronavirus disease of 2019 (COVID-19) pneumonia. Results 90 of 127 patients (71%) survived. Mortality was highest in the elderly with multiple medical conditions. Conclusion Despite the small sample size and retrospective nature of the work, our findings are consistent with recent studies suggesting tocilizumab administration in patients presenting with severe COVID pneumonia with associated hyperinflammatory features conferred mortality benefit.

Bioanalysis of aminoglycosides using high-performance liquid chromatography

“…Indeed, several studies have used HPLC for the bioanalysis of aminoglycosides [14][15][16]. Although there are recently published reviews on aminoglycosides, the focus of these reviews have been a) pre-treatment and analysis methods of aminoglycosides in food [17], b) challenges in the development of analytical test procedures for aminoglycosides [18], and c) determination of kanamycin by high-performance liquid chromatography [19].…”

Determination of the cut-off score of Human platelets membrane glycoprotein IIb/IIIa in COVID19: A novel biomarker and a therapeutic target

“…Determination of Human platelets membrane glycoprotein IIb/IIIa (CD41/CD61) GPIIb/IIIa using ELISA technique was based on preparation of microparticle-free plasma. It was prepared by double centrifugation of anti-coagulated blood; first centrifugation was at 3000 xg for 15 min, then centrifuge the supernatant at 20000 xg for 30 min [14].…”